We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Hikma Pharmaceuticals (HIK) Ordinary GBP 0.10

Sell:1,983.00p Buy:1,985.00p 0 Change: 16.00p (0.80%)
FTSE 100:0.63%
Market closed Prices as at close on 13 June 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1,983.00p
Buy:1,985.00p
Change: 16.00p (0.80%)
Market closed Prices as at close on 13 June 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1,983.00p
Buy:1,985.00p
Change: 16.00p (0.80%)
Market closed Prices as at close on 13 June 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio. Its subsidiaries include Al Jazeera Pharmaceutical Industry S.A.R.L, Hikma Pharma Algeria S.A.R.L. and others.

Contact details

Address:
1 New Burlington Place
LONDON
W1S 2HR
United Kingdom
Telephone:
+44 (020) 73992760
Website:
https://www.hikma.com/

Important dates

Future events
Interim results 08 August 2024 08/08/24
Past events
Final dividend payment date 03 May 2024 03/05/24
AGM 25 April 2024 25/04/24
Trading Announcement 25 April 2024 25/04/24
Annual report 22 March 2024 22/03/24
Final ex-dividend date 21 March 2024 21/03/24
Final results 22 February 2024 22/02/24
Trading Announcement 02 November 2023 02/11/23
Interim dividend payment date 15 September 2023 15/09/23
Interim ex-dividend date 10 August 2023 10/08/23
Interim results 03 August 2023 03/08/23

General stock information

EPIC:
HIK
ISIN:
GB00B0LCW083
Market cap:
£4.42 billion
Shares in issue:
221.89 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE 100,FTSE 350,FTSE All Share

Key personnel

  • Said Darwazah
    Executive Chairman of the Board
  • Riad Mishlawi
    Chief Executive Officer, Executive Director
  • Mazen Darwazah
    Executive Vice Chairman of the Board, President of MENA
  • Khalid Nabilsi
    Chief Financial Officer
  • Hafrun Fridriksdottir
    President - Generics
  • Bill Larkins
    President - Injectables
  • Hussein Arkhagha
    Chief People Officer
  • Susan Ringdal
    Executive Vice President - Strategic Planning and Global Affairs
  • Bassam Wael Roshdi Kanaan
    Executive Vice President - Corporate Development and M and A
  • Julie Hill
    Senior Vice President - Corporate Quality Compliance and Health and Safety

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.